Antonio Lamb

Antonio is a Swedish molecular biologist and entrepreneur from California with expertise in the animal and human pharmaceutical industries. He is a co-founder of MicroSynbiotiX (now acquired by Sundew), developing plant-based oral vaccines and therapeutics for the aquaculture industry.

Antonio obtained his B.Sc. from the University of California, Santa Cruz, his M.Sc. from the University of Basel in molecular biology, and is currently in the Microbiology and Immunology PhD program at the University of Zurich/ETH Zurich. Antonio also works as a scientist at the Novartis Institutes of BioMedical Research, where he conducts CRISPR genetic screening of advanced 3D cell culture models to find new druggable disease targets.